| 肺癌肿瘤抑制物-1基因在肾腺癌伴骨转移组织的表达及临床意义 |
| |
| 引用本文： | 陈剑锋,陈安民,郭风劲,赵文斌,袁雪峰,王茂朋,张帆. 肺癌肿瘤抑制物-1基因在肾腺癌伴骨转移组织的表达及临床意义[J]. 中国全科医学, 2011, 14(36) |
| |
| 作者姓名： | 陈剑锋 陈安民 郭风劲 赵文斌 袁雪峰 王茂朋 张帆 |
| |
| 作者单位： | 华中科技大学同济医学院附属同济医院骨科,湖北省武汉市,430030 |
| |
| 摘 要： | 目的探讨肺癌肿瘤抑制物-1(TSLC1)基因在肾腺癌伴骨转移组织中的表达及其与临床病理特征的关系。方法采用免疫组织化学(SP)法检测TSLC1在54例肾腺癌无骨转移患者的癌组织标本,10例肾腺癌伴骨转移患者的癌组织标本及10例正常肾组织中的表达。结果 TSLC1蛋白在肾腺癌无骨转移患者的癌组织中阳性表达率为53.7%(29/54),在肾腺癌伴骨转移患者的癌组织中阳性表达率为2/10,在正常肾组织中的阳性表达率为10/10,三组间差异有统计学意义(P<0.05)。TSLC1蛋白在肾腺癌病理分级Ⅰ～Ⅱ级中阳性表达率为54.0%,在Ⅲ级中阳性表达率为21.4%,差异有统计学意义(P<0.05);在肾腺癌伴发骨转移患者的癌组织中阳性表达率为20.0%,在无骨转移患者的癌组织中阳性表达率为61.1%,差异有统计学意义(P<0.05)。结论 TSLC1基因可能与肾腺癌伴发骨转移的发生、发展有关,可能对肾腺癌伴发骨转移的早期诊断及预后评估具有重要意义。
|
| 关 键 词： | 肾腺癌 肺癌肿瘤抑制物-1 免疫组织化学 骨转移 |
Expression and Clinical Significance of TSLC1 Gene in Renal Adenocarcinoma with Bone Metastasis |
| |
| CHEN Jian-feng,CHEN An-min,GUO Feng-jin,et al.. Expression and Clinical Significance of TSLC1 Gene in Renal Adenocarcinoma with Bone Metastasis[J]. Chinese General Practice, 2011, 14(36) |
| |
| Authors: | CHEN Jian-feng CHEN An-min GUO Feng-jin et al. |
| |
| Affiliation: | CHEN Jian-feng,CHEN An-min,GUO Feng-jin,et al.Department of Orthopedics,Affiliated Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China |
| |
| Abstract: | Objective To discuss the relationship between the expressions of tumor suppresser in lung cancer 1(TSLC1) gene and the clinical and pathological features of renal adenocarcinoma with bone metastasis.Methods The expression of TSLC1 were detected by SP immunohistochemical method in 74 samples(54 were from renal adenocarcinoma,10 were from renal adenocarcinoma with bone metastasis and 10 were from normal renal tissues).Results The positive expression rates of TSLC1 were 53.7%(29/54) in renal adenocarcinoma,2/1... |
| |
| Keywords: | Renal adenocarcinoma Tumor suppresser in lung cancer 1 Immunohistochemistry Bone metastasis |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
